Multiple sclerosis is a chronic immune-mediated disease of the central nervous system in which inflammatory demyelination and neurodegeneration disrupt neural transmission and cause variable neurological disability.
Silo Pharma received a European patent grant and a Japan patent allowance for SPC-15, its intranasal PTSD prevention candidate. The patents cover methods using serotonin 4 receptor agonists to prevent stress-induced psychiatric disorders.
FDA cleared Quantum Biopharma's IND for a Phase 2 trial of Lucid-MS in MS. Biogen's BIIB091 Phase 2 trial reached completion, and Bial concluded its ACTIVATE Phase IIb treatment period for GBA-PD.
CAR-T therapy reaches 150 patients in Ireland and expands into autoimmune trials for lupus and MS. Kyverna's miv-cel nears FDA approval for stiff person syndrome, and new research links gene variants to CAR-T outcomes.
Roche stock trades steadily as group sales reach the mid-CHF 60 billion range. Q1 2025 revenue edged higher, and 2025 guidance points to low to mid single digit sales growth.
Federal courts are weighing whether the April 2026 marijuana rescheduling order was lawful. MMJ argues the Attorney General skipped required rulemaking; DEA testimony flagged omitted diversion analysis. A stay motion is pending.
Novartis beat second-quarter profit expectations as Kisqali, Kesimpta and Leqvio offset a 50% plunge in Entresto sales. The Swiss drugmaker maintained its full-year guidance and awaits late-stage data on three experimental drugs.
Two new studies clarify how Epstein-Barr virus may trigger multiple sclerosis: one shows a doubled CD4+ T cell response in untreated patients, while another reveals EBV-activated B cells cause brain inflammation in mice. Insights point to potential therapies targeting EBV-specific immune activity.
A new gene therapy platform uses the brain's glymphatic system to deliver genes to glial cells throughout the brain. It bypasses the blood-brain barrier and could enable treatments for multiple sclerosis, Huntington's disease, and rare childhood white matter disorders.
Biogen's Phase 2 CELIA trial showed diranersen slowed Alzheimer's decline and cut tau biomarkers, but missed the dose-response goal. Leqembi sales data is expected next quarter.
Two new studies advance Lyme disease research: anti-lipid antibodies may enable earlier diagnosis and detect persistent symptoms, while cell wall changes in Borrelia burgdorferi offer insights into Lyme arthritis pathogenesis and potential treatment targets.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07779460 |
A Study Comparing Effectiveness of Kesimpta® (Ofatumumab) Versus Ocrevus® (Ocrelizumab) in Real-world Practice |
RECRUITING | |
| NCT07770620 |
Effects of Face-to-Face Versus Telerehabilitation-Based Circuit Training in People With Multiple Sclerosis |
NOT_YET_RECRUITING | NA |
| NCT07769294 |
PLasmatic Extracellular Vesicles AS Biomarkers of nEural Tissue Damage |
NOT_YET_RECRUITING | |
| NCT07768761 |
Electrical Stimulation Exercise for Individuals With Lower Limb Paralysis |
RECRUITING | NA |
| NCT07766213 |
Pain Phenotypes in Individuals With Multiple Sclerosis |
NOT_YET_RECRUITING | |
| NCT07765212 |
Evaluating the Use of Oral Indapamide to Reduce Disabiltiy Progression in Progressive Multiple Sclerosis (MS) |
NOT_YET_RECRUITING | PHASE2 |
| NCT07762326 |
Effect of Artificial Intelligence Based Cognitive Training on Sleep Disorders and Quality of Life in Patients With Multiple Sclerosis |
NOT_YET_RECRUITING | NA |
| NCT07762040 |
Predictors of Progression Independent of Relapse Activity in Relapsing Remitting Multiple Sclerosis |
NOT_YET_RECRUITING | |
| NCT07759115 |
Music-4-MS to Improve Cognition in People Living With Multiple Sclerosis: A Feasibility Study |
RECRUITING | NA |
| NCT07756268 |
Phase Ib/II Study of SYS6020 in Relapsing/Refractory Multiple Sclerosis |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
